138 related articles for article (PubMed ID: 34353213)
1. Economic implications of the modern treatment paradigm of glioblastoma: an analysis of global cost estimates and their utility for cost assessment.
Goel NJ; Bird CE; Hicks WH; Abdullah KG
J Med Econ; 2021; 24(1):1018-1024. PubMed ID: 34353213
[TBL] [Abstract][Full Text] [Related]
2. Can we afford to add chemotherapy to radiotherapy for glioblastoma multiforme? Cost-identification analysis of concomitant and adjuvant treatment with temozolomide until patient death.
Wasserfallen JB; Ostermann S; Pica A; Mirimanoff RO; Leyvraz S; Villemure JG; Stupp R
Cancer; 2004 Nov; 101(9):2098-105. PubMed ID: 15389472
[TBL] [Abstract][Full Text] [Related]
3. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
4. Management of glioblastoma: comparison of clinical practices and cost-effectiveness in two cohorts of patients (2008 versus 2004) diagnosed in a French university hospital.
Diebold G; Ducray F; Henaine AM; Frappaz D; Guyotat J; Cartalat-Carel S; Breant V; Fouquet A; Aulagner G; Honnorat J; Armoiry X
J Clin Pharm Ther; 2014 Dec; 39(6):642-8. PubMed ID: 25164371
[TBL] [Abstract][Full Text] [Related]
5. Clinical and economic evaluation of modulated electrohyperthermia concurrent to dose-dense temozolomide 21/28 days regimen in the treatment of recurrent glioblastoma: a retrospective analysis of a two-centre German cohort trial with systematic comparison and effect-to-treatment analysis.
Roussakow SV
BMJ Open; 2017 Nov; 7(11):e017387. PubMed ID: 29102988
[TBL] [Abstract][Full Text] [Related]
6. Recurrent glioblastomas in the elderly after maximal first-line treatment: does preserved overall condition warrant a maximal second-line treatment?
Zanello M; Roux A; Ursu R; Peeters S; Bauchet L; Noel G; Guyotat J; Le Reste PJ; Faillot T; Litre F; Desse N; Emery E; Petit A; Peltier J; Voirin J; Caire F; Barat JL; Vignes JR; Menei P; Langlois O; Dezamis E; Carpentier A; Dam Hieu P; Metellus P; Pallud J;
J Neurooncol; 2017 Nov; 135(2):285-297. PubMed ID: 28726173
[TBL] [Abstract][Full Text] [Related]
7. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
[TBL] [Abstract][Full Text] [Related]
8. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
Hind D; Tappenden P; Tumur I; Eggington S; Sutcliffe P; Ryan A
Health Technol Assess; 2008 May; 12(15):iii-ix, xi-162. PubMed ID: 18462574
[TBL] [Abstract][Full Text] [Related]
9. Anti-epidermal growth factor receptor therapy for glioblastoma in adults.
Lee A; Arasaratnam M; Chan DLH; Khasraw M; Howell VM; Wheeler H
Cochrane Database Syst Rev; 2020 May; 5(5):CD013238. PubMed ID: 32395825
[TBL] [Abstract][Full Text] [Related]
10. Cost of temozolomide therapy and global care for recurrent malignant gliomas followed until death.
Wasserfallen JB; Ostermann S; Leyvraz S; Stupp R
Neuro Oncol; 2005 Apr; 7(2):189-95. PubMed ID: 15831237
[TBL] [Abstract][Full Text] [Related]
11. The clinical effectiveness and cost-effectiveness of different surveillance mammography regimens after the treatment for primary breast cancer: systematic reviews registry database analyses and economic evaluation.
Robertson C; Arcot Ragupathy SK; Boachie C; Dixon JM; Fraser C; Hernández R; Heys S; Jack W; Kerr GR; Lawrence G; MacLennan G; Maxwell A; McGregor J; Mowatt G; Pinder S; Ternent L; Thomas RE; Vale L; Wilson R; Zhu S; Gilbert FJ
Health Technol Assess; 2011 Sep; 15(34):v-vi, 1-322. PubMed ID: 21951942
[TBL] [Abstract][Full Text] [Related]
12. Positron emission tomography/computerised tomography imaging in detecting and managing recurrent cervical cancer: systematic review of evidence, elicitation of subjective probabilities and economic modelling.
Meads C; Auguste P; Davenport C; Małysiak S; Sundar S; Kowalska M; Zapalska A; Guest P; Thangaratinam S; Martin-Hirsch P; Borowiack E; Barton P; Roberts T; Khan K
Health Technol Assess; 2013 Mar; 17(12):1-323. PubMed ID: 23537558
[TBL] [Abstract][Full Text] [Related]
13. Economics of Malignant Gliomas: A Critical Review.
Raizer JJ; Fitzner KA; Jacobs DI; Bennett CL; Liebling DB; Luu TH; Trifilio SM; Grimm SA; Fisher MJ; Haleem MS; Ray PS; McKoy JM; DeBoer R; Tulas KM; Deeb M; McKoy JM
J Oncol Pract; 2015 Jan; 11(1):e59-65. PubMed ID: 25466707
[TBL] [Abstract][Full Text] [Related]
14. Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of emerging developments in the management of newly diagnosed glioblastoma.
Farrell C; Shi W; Bodman A; Olson JJ
J Neurooncol; 2020 Nov; 150(2):269-359. PubMed ID: 33215345
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in therapy for glioblastoma.
Clarke J; Butowski N; Chang S
Arch Neurol; 2010 Mar; 67(3):279-83. PubMed ID: 20212224
[TBL] [Abstract][Full Text] [Related]
16. Benefit of re-operation and salvage therapies for recurrent glioblastoma multiforme: results from a single institution.
Azoulay M; Santos F; Shenouda G; Petrecca K; Oweida A; Guiot MC; Owen S; Panet-Raymond V; Souhami L; Abdulkarim BS
J Neurooncol; 2017 May; 132(3):419-426. PubMed ID: 28374095
[TBL] [Abstract][Full Text] [Related]
17. Economic evaluation of temozolomide in the treatment of recurrent glioblastoma multiforme.
Martikainen JA; Kivioja A; Hallinen T; Vihinen P
Pharmacoeconomics; 2005; 23(8):803-15. PubMed ID: 16097842
[TBL] [Abstract][Full Text] [Related]
18. A cost-effectiveness and cost-utility analysis of radiosurgery vs. resection for single-brain metastases.
Mehta M; Noyes W; Craig B; Lamond J; Auchter R; French M; Johnson M; Levin A; Badie B; Robbins I; Kinsella T
Int J Radiat Oncol Biol Phys; 1997 Sep; 39(2):445-54. PubMed ID: 9308949
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
